{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:40:01Z","timestamp":1756363201831,"version":"3.44.0"},"reference-count":21,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,1,27]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>Bevacizumab (bev) significantly improves outcomes of patients with metastatic colorectal cancer (mCRC). However, the addition of bev to concurrent chemotherapy significantly increased the risk of haemorrhage. We describe the case of a patient with mCRC who presented with acute diffuse abdominal pain following four cycles of bev-containing systemic chemotherapy. A CT revealed the appearance of bilateral adrenal enlargement suggestive of acute adrenal haematoma. Blood test results showed a dramatic decrease in cortisol level and highly elevated Adrenocorticotropic Hormone (ACTH) level suggesting an adrenal insufficiency. After differential diagnosis, we hypothesised that bev may have contributed to the development of a bilateral adrenal haematoma complicated by adrenal insufficiency. Bev was immediately withdrawn and the patient was subsequently treated with hydrocortisone substitution with favourable outcome. This case highlights for the first time the possibility of adrenal bleeding with bev-containing chemotherapy.<\/jats:p>","DOI":"10.1136\/bcr-2020-239689","type":"journal-article","created":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T11:36:18Z","timestamp":1613993778000},"page":"e239689","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Bilateral adrenal haematoma complicated by adrenal insufficiency in a patient treated with bevacizumab"],"prefix":"10.1136","volume":"14","author":[{"given":"Cristina","family":"Smolenschi","sequence":"first","affiliation":[{"name":"Departement of Medical Oncology, Gustave Roussy Institute, Villejuif, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melodie","family":"Tazdait","sequence":"additional","affiliation":[{"name":"Departement of Medical Oncology, Gustave Roussy Institute, Villejuif, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuelle","family":"Kuhn","sequence":"additional","affiliation":[{"name":"Endocrine Departement, Hospital Bicetre, Le Kremlin-Bicetre, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Boige","sequence":"additional","affiliation":[{"name":"Departement of Medical Oncology, Gustave Roussy Institute, Villejuif, \u00cele-de-France, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"2025082723074805000_14.2.e239689.1","doi-asserted-by":"publisher","DOI":"10.1007\/s11934-009-0014-y"},{"key":"2025082723074805000_14.2.e239689.2","unstructured":"FDA . Avastin (bevacizumab) information. Available: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/avastin-bevacizumab-information"},{"key":"2025082723074805000_14.2.e239689.3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089960"},{"key":"2025082723074805000_14.2.e239689.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.51"},{"key":"2025082723074805000_14.2.e239689.5","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004232","article-title":"Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: an updated meta-analysis of 12 randomized controlled trials","volume":"95","author":"Zhu","year":"2016","journal-title":"Medicine"},{"key":"2025082723074805000_14.2.e239689.6","first-page":"4682","article-title":"Ras oncogenes in human cancer: a review","volume":"49","author":"Bos","year":"1989","journal-title":"Cancer Res"},{"key":"2025082723074805000_14.2.e239689.7","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1016\/j.ejca.2015.05.017","article-title":"Prevalence of Ras mutations and individual variation patterns among patients with metastatic colorectal cancer: a pooled analysis of randomised controlled trials","volume":"51","author":"Peeters","year":"2015","journal-title":"Eur J Cancer"},{"key":"2025082723074805000_14.2.e239689.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70330-4"},{"key":"2025082723074805000_14.2.e239689.9","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1159\/000452551","article-title":"Efficacy of bevacizumab in the first-line treatment of patients with Ras mutations metastatic colorectal cancer: a systematic review and network meta-analysis","volume":"40","author":"Zhou","year":"2016","journal-title":"Cell Physiol Biochem"},{"key":"2025082723074805000_14.2.e239689.10","first-page":"15","article-title":"Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection","volume":"12","author":"Constantinidou","year":"2013","journal-title":"Clin Colorectal Cancer"},{"key":"2025082723074805000_14.2.e239689.11","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1200\/JCO.20.00174","article-title":"Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial","volume":"38","author":"Tang","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025082723074805000_14.2.e239689.12","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-008-0035-7"},{"key":"2025082723074805000_14.2.e239689.13","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2174\/1871520619666190417162409","article-title":"Bevacizumab allows preservation of liver function and its regenerative capacity after major hepatectomy","volume":"19","author":"Valverde","year":"2019","journal-title":"Anticancer Agents Med Chem"},{"key":"2025082723074805000_14.2.e239689.14","unstructured":"Medscape . Adrenal hemorrhage. Available: https:\/\/emedicine.medscape.com\/article\/126806-overview"},{"key":"2025082723074805000_14.2.e239689.15","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.3892\/ol.2016.4328","article-title":"Perirenal hematoma in a patient treated with bevacizumab for metastatic colon cancer: a case report","volume":"11","author":"Lee","year":"2016","journal-title":"Oncol Lett"},{"key":"2025082723074805000_14.2.e239689.16","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.11.7973"},{"key":"2025082723074805000_14.2.e239689.17","doi-asserted-by":"crossref","DOI":"10.4103\/2156-7514.124088","article-title":"Adrenal lesions: spectrum of imaging findings with emphasis on multi-detector computed tomography and magnetic resonance imaging","volume":"3","author":"Guerrisi","year":"2013","journal-title":"J Clin Imaging Sci"},{"key":"2025082723074805000_14.2.e239689.18","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cjtee.2016.05.002","article-title":"Imaging of unilateral adrenal hemorrhages in patients after blunt abdominal trauma: report of two cases","volume":"20","author":"Sayit","year":"2017","journal-title":"Chin J Traumatol"},{"key":"2025082723074805000_14.2.e239689.19","doi-asserted-by":"crossref","DOI":"10.1186\/1752-1947-9-18","article-title":"Restoration of adrenal function after bilateral adrenal damage due to heparin-induced thrombocytopenia (HIT): a case report","volume":"9","author":"Jaafar","year":"2015","journal-title":"J Med Case Rep"},{"key":"2025082723074805000_14.2.e239689.20","doi-asserted-by":"crossref","unstructured":"Ansar M , Morselli L , Shibli-Rahhal A . MON-345 recovery of adrenal function following bilateral adrenal hemorrhage: two case reports. J Endocr Soc 2019;3.doi:10.1210\/js.2019-MON-345","DOI":"10.1210\/js.2019-MON-345"},{"key":"2025082723074805000_14.2.e239689.21","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0664-8"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-239689","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:07:56Z","timestamp":1756361276000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-239689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,22]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/bcr-2020-239689"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-239689","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}